Published in J Exp Med on April 25, 2005
Immune Signature of Palmoplantar Pustulosis (PPP) | NCT01780857
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol (2009) 5.91
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 5.61
The IL-1 family: regulators of immunity. Nat Rev Immunol (2010) 4.65
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 4.40
Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity (2010) 3.67
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol (2013) 3.55
Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med (2007) 3.51
Blocking IL-1 in systemic inflammation. J Exp Med (2005) 3.37
Anti-inflammatory Agents: Present and Future. Cell (2010) 3.13
IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol (2010) 2.99
IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest (2007) 2.88
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
Systems biology in immunology: a computational modeling perspective. Annu Rev Immunol (2011) 2.15
Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev (2008) 2.13
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med (2006) 2.11
A genomic approach to human autoimmune diseases. Annu Rev Immunol (2010) 2.10
Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab (2014) 1.96
Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev (2010) 1.96
Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol (2010) 1.95
Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis (2006) 1.95
Assessing the human immune system through blood transcriptomics. BMC Biol (2010) 1.86
Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One (2009) 1.79
Treating inflammation by blocking interleukin-1 in humans. Semin Immunol (2013) 1.75
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol (2011) 1.67
Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci (2011) 1.65
RNA recognition by human TLR8 can lead to autoimmune inflammation. J Exp Med (2013) 1.64
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 1.51
Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood (2006) 1.48
Harnessing human dendritic cell subsets for medicine. Immunol Rev (2010) 1.46
Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum (2012) 1.40
Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol (2009) 1.38
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med (2011) 1.35
Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. Proc Natl Acad Sci U S A (2010) 1.34
Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol (2012) 1.34
Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A (2011) 1.33
High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol (2010) 1.33
S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum (2008) 1.33
Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol (2012) 1.30
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol (2008) 1.29
Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther (2009) 1.26
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci (2009) 1.25
Interleukin-1β inhibition prevents choroidal neovascularization and does not exacerbate photoreceptor degeneration. Am J Pathol (2011) 1.22
Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med (2011) 1.21
Microarray-based identification of novel biomarkers in IL-1-mediated diseases. Curr Opin Immunol (2007) 1.21
Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol (2010) 1.20
Pattern recognition by pentraxins. Adv Exp Med Biol (2009) 1.19
Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. J Exp Med (2010) 1.18
Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm (2009) 1.17
Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS One (2011) 1.17
Canakinumab. MAbs (2010) 1.16
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med (2011) 1.16
How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev (2008) 1.15
The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases. Front Immunol (2013) 1.11
Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum (2010) 1.10
IL-1 blockade in autoinflammatory syndromes. Annu Rev Med (2014) 1.10
Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond) (2011) 1.10
Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review. Curr Genomics (2010) 1.08
Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2. J Immunol (2009) 1.06
Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am (2010) 1.06
Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol (2014) 1.06
Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol (2009) 1.05
Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol (2009) 1.05
Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am (2012) 1.05
Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther (2011) 1.04
Multiple interleukin-1beta-converting enzymes contribute to inflammatory arthritis. Arthritis Rheum (2009) 1.04
Transcriptional signatures as a disease-specific and predictive inflammatory biomarker for type 1 diabetes. Genes Immun (2012) 1.04
Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum (2013) 1.01
Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol (2008) 1.01
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) (2015) 1.01
Polymorphic variability in the interleukin (IL)-1beta promoter conditions susceptibility to severe malarial anemia and functional changes in IL-1beta production. J Infect Dis (2008) 1.00
Sensors of the innate immune system: their link to rheumatic diseases. Nat Rev Rheumatol (2010) 1.00
Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep (2011) 0.97
Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis. Core Evid (2010) 0.96
Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics (2010) 0.96
Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res Ther (2006) 0.96
Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2013) 0.95
Identification of a serum-induced transcriptional signature associated with type 1 diabetes in the BioBreeding rat. Diabetes (2010) 0.95
Update on the pathogenesis and treatment of systemic idiopathic arthritis. Curr Opin Pediatr (2011) 0.95
Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam (2011) 0.94
Update on genetics and pathogenesis of autoinflammatory diseases: the last 2 years. Semin Immunopathol (2015) 0.94
Neutrophils: the forgotten cell in JIA disease pathogenesis. Pediatr Rheumatol Online J (2007) 0.94
Costimulatory effects of IL-1 on the expansion/differentiation of CD4+CD25+Foxp3+ and CD4+CD25+Foxp3- T cells. J Leukoc Biol (2008) 0.94
The comparative study of Sprague-Dawley and Lewis rats in adjuvant-induced arthritis. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.94
Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J (2014) 0.93
Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir Res (2010) 0.93
Is the inflammasome a potential therapeutic target in renal disease? BMC Nephrol (2014) 0.92
Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford) (2012) 0.92
Familial Mediterranean fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6-10 November 2005. Ann Rheum Dis (2006) 0.91
Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep (2014) 0.90
An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol (2010) 0.90
Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet (2012) 0.90
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. MAbs (2011) 0.90
C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nat Immunol (2016) 0.90
Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol (2007) 0.89
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm (2015) 0.89
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 8.14
Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum (2004) 7.07
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum (2002) 4.98
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med (2000) 4.76
Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet (2004) 4.23
Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med (2000) 4.06
Chemokines: multiple levels of leukocyte migration control. Trends Immunol (2004) 3.32
The IL-1 family and inflammatory diseases. Clin Exp Rheumatol (2004) 3.10
Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc Natl Acad Sci U S A (2004) 3.05
Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum (1991) 2.91
A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum (1986) 2.56
Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum (2004) 2.47
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 2.35
Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A (2003) 2.30
The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis (2004) 2.16
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum (2003) 2.03
Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol (2000) 1.88
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol (2004) 1.57
Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum (2000) 1.52
Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am (1991) 1.50
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum (2003) 1.42
Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum (2002) 1.36
Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol (2004) 1.34
Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin Exp Rheumatol (2004) 1.34
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol (2003) 1.28
Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. Clin Exp Rheumatol (2001) 1.06
CCR1 chemokine receptor antagonist. Curr Pharm Des (2003) 1.03
Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol (1998) 0.99
The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol (1998) 0.93
Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J Rheumatol (2002) 0.93
Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr (2002) 0.90
Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis. Curr Rheumatol Rep (2000) 0.87
Taking dendritic cells into medicine. Nature (2007) 11.82
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature (2010) 10.37
Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity (2011) 5.98
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood (2006) 5.05
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity (2003) 4.93
Pyogenic bacterial infections in humans with MyD88 deficiency. Science (2008) 4.92
Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol (2008) 4.78
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med (2011) 4.51
Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity (2008) 3.94
Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity (2007) 3.58
Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med (2007) 3.51
Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity (2009) 3.13
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med (2011) 3.12
Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol (2006) 2.99
Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol (2008) 2.82
Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A (2005) 2.73
Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med (2013) 2.64
Dendritic cell subsets in health and disease. Immunol Rev (2007) 2.45
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature (2010) 2.31
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med (2007) 2.25
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol (2005) 2.16
Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev (2008) 2.13
A genomic approach to human autoimmune diseases. Annu Rev Immunol (2010) 2.10
Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity (2013) 2.08
Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 2.04
Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol (2009) 2.04
Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab (2007) 2.00
Taming cancer by inducing immunity via dendritic cells. Immunol Rev (2007) 1.92
Assessing the human immune system through blood transcriptomics. BMC Biol (2010) 1.86
Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One (2013) 1.86
Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice. Eur J Immunol (2008) 1.84
Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One (2009) 1.79
Recent developments in cancer vaccines. J Immunol (2011) 1.76
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 1.75
Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood (2005) 1.75
Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice. Eur J Immunol (2011) 1.73
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol (2003) 1.69
How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr Opin Immunol (2002) 1.68
Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One (2012) 1.68
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2007) 1.66
Regional distribution of adult rheumatologists. Arthritis Rheum (2013) 1.58
Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood (2010) 1.55
Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med (2013) 1.53
Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers. Proc Natl Acad Sci U S A (2011) 1.50
Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med (2012) 1.50
H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol (2013) 1.48
Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis (2005) 1.46
Harnessing human dendritic cell subsets for medicine. Immunol Rev (2010) 1.46
IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol (2007) 1.45
TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol (2003) 1.40
Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Ann Rheum Dis (2013) 1.39
The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol (2009) 1.35
A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity (2009) 1.33
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.33
IL-12 receptor β1 deficiency alters in vivo T follicular helper cell response in humans. Blood (2013) 1.31
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol (2008) 1.29
Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann N Y Acad Sci (2005) 1.28
Host immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infections. PLoS One (2012) 1.28
The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum (2010) 1.28
Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun (2005) 1.26
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum (2010) 1.24
CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol (2009) 1.23
Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-β. Immunity (2013) 1.23
Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors. Blood (2003) 1.23
Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med (2004) 1.22
Microarray-based identification of novel biomarkers in IL-1-mediated diseases. Curr Opin Immunol (2007) 1.21
Update on pediatric systemic lupus erythematosus. Curr Opin Rheumatol (2004) 1.19
Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8+ T cell responses. J Immunol (2010) 1.16
How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev (2008) 1.15
Differential recruitment of dendritic cells and monocytes to respiratory mucosal sites in children with influenza virus or respiratory syncytial virus infection. J Infect Dis (2008) 1.13
Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods (2010) 1.13
Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood (2008) 1.12
Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum Immunol (2002) 1.12
Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol (2004) 1.12
Health-related quality of life and its relationship to patient disease course in childhood-onset systemic lupus erythematosus. J Rheumatol (2009) 1.10
Targeting human dendritic cell subsets for improved vaccines. Semin Immunol (2011) 1.09
Human dendritic cell subsets for vaccination. J Clin Immunol (2005) 1.09
Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation. J Exp Med (2012) 1.08
Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review. Curr Genomics (2010) 1.08